all report title image
  • Published On : Jan 2023
  • Code : CMI712
  • Industry : Pharmaceutical
  • Pages : 170
  • Formats :

The global atopic dermatitis market was valued at US$ 7,795.3 Mn in 2021 and is forecast to reach a value of US$ 14,941.2 Mn by 2028 at a CAGR of 9.7% between 2022 and 2028. The global atopic dermatitis market is experiencing strong growth due to the increasing prevalence of atopic dermatitis and increasing awareness among people about atopic dermatitis. Moreover, increase in focus on the development of novel therapeutics and outbreak of COVID-19 is expected to boost the growth of the market. However, factors such as adverse effects of certain therapeutic drugs and treatment cost variations limit patient access are expected to hamper the market growth.

Global Atopic Dermatitis Market: Regional Insights

Based on geography, the global atopic dermatitis market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing incidence of atopic dermatitis, increasing awareness among people about atopic dermatitis, and government campaigns to raise awareness in the region. For instance, atopic dermatitis (eczema) is the condition that causes dry, itchy, and inflamed skin. According to the Asthma and Allergy Foundation of America, the most common form of eczema, AD (atopic dermatitis) leads to significant emotional burden in addition to pain, physical discomfort, and sleep disturbance for 16.5 million adults in the United States.

Europe is also expected to witness robust growth in the global atopic dermatitis market due to the growing prevalence of atopic dermatitis and strategic initiatives undertaken by the government and market players in the region. For instance, according to the European Medicines Agency (EMA), European Union, In Europe, it is estimated that up to 7% of adults have atopic dermatitis and the proportion of adults with the moderate to severe form of the disease is around 30%. Moreover, one in four adults with the disease report its onset in adulthood. This in turn is expected to drive growth of the atopic dermatitis market in the region (Europe).

Figure 1. Global Atopic Dermatitis Market Share (%), by Region, 2021

Global Atopic Dermatitis Market Drivers:

Growing prevalence of atopic dermatitis to augment the market growth

One of the key factors expected to augment the growth of the global atopic dermatitis market over the forecast period is the rise in prevalence of atopic dermatitis across the globe. Atopic dermatitis, also known as eczema, is a chronic disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, people of all ages live with a condition. According to the World Health Organization (WHO) Global Burden of Diseases initiative, more than 230 million people across the world have atopic eczema, and this number is expected to increase during the forecast period.

Increasing awareness among people to underpin market growth

Another factor which is driving the growth of the global atopic dermatitis market is the increasing awareness among people about atopic dermatitis. Atopic eczema is one of the most prevalent skin diseases in the world. Thus, governments worldwide and players in the market are launching novel initiative/campaign to raise atopic dermatitis awareness. For instance, Atopic Eczema Community comes together on September 14th (every year) to raise awareness for the disease, speak up about the burden it has on patients and caregivers, and to recognize the need for care and treatment that is reflective of the multi-dimensional nature of the disease.

CMI table icon

Atopic Dermatitis Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 7,795.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 9.7% 2028 Value Projection: US$ 14,941.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Corticosteroids, Emollients/Moisturizers, IL-4 & PDE4 Inhibitors, Calcineurin Inhibitors Antibiotics, and Other Drug Classes
  • By Type of Administration: Topical, Oral, and Injectable), By Prescription Type (Over-the-counter (OTC) and Prescription
Companies covered:

Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.

Growth Drivers:
  • Growing prevalence of atopic dermatitis worldwide
  • Increasing consumer awareness about atopic dermatitis
Restraints & Challenges:
  • Serious adverse effects of certain therapeutic drugs
  • Treatment cost variations limit patient access

Global Atopic Dermatitis Market Opportunities:

Increase in focus on the development of novel therapeutics is expected to offer significant growth opportunities for players in the global atopic dermatitis market. For instance, players in the market are focusing on launching novel therapeutics owing to rise in burden of atopic dermatitis. On the World Atopic Dermatitis Day, Sanofi and Regeneron announced the launch of new, global grants initiative seeking proposals for grassroot solutions to help solve some of the greatest challenges impacting people living with atopic dermatitis (AD).

Outbreak of COVID-19 across the world is expected to offer significant growth opportunities for players in the global atopic dermatitis market. For instance, the global pandemic has had a positive impact on the growth of the market due to increase in frequency of hand-washing by the population following safety and sanitation/hygiene measures, which helps in containing the spread of SARS-CoV-2 (COVID-19). Constant exposure to soap and water has increased dry skin, leading to an increase in cases of hand atopic dermatitis, driving the market growth.

Global Atopic Dermatitis Market Trends:

Increase in demand for safe/effective treatment is a recent trend

With the rise in prevalence of atopic dermatitis, the demand for safe and effective AD treatment. As a result, players in the market are focusing on developing and launching novel therapeutics in the market. Left untreated, eczema can lead to severe symptoms and increased risk of developing secondary infections. In severe long-term cases, untreated childhood eczema may interfere with growth and development.

Increase in use of atopic dermatitis drugs is another trend

Topical corticosteroids have been the mainstay of treatment for atopic dermatitis over the years. Corticosteroids are used as pain relief medicines for inflammation in the body. Corticosteroids are known to reduce itching, redness, swelling, and allergic reactions. Clinical trials have also shown that topical corticosteroids are safe and effective to treat atopic dermatitis flare-ups.

Global Atopic Dermatitis Market Restraints:

Side effects of therapeutic drugs are hindering the market growth

One of the major factors hindering the market growth is the serious adverse effects associated with certain therapeutic drugs. Individuals with atopic dermatitis are at risk of developing food allergies, asthma, hay fever, itchy/scaly skin, skin infections, mental health conditions, sleep problems, and patches of skin that's darker or lighter than the surrounding area. However, developing a basic skin care routine (use a gentle/non-soap cleanser, daily bath or shower, and skin moisturize) may help prevent eczema flares as the triggers for AD vary widely from person to person.

High cost of treatment to hamper the growth of the market

Treatment cost variations (which limits patient access) is another major factor which is hampering the market growth. Atopic dermatitis is often associated with increased physician visits, emergency department visits, and hospitalizations. The cost of care is even higher with rising chronic physical illness and severely ill-patients. Moreover, in some emerging markets, AD causes a considerable consumption of financial resources as the treatment is often self-funded.

Figure 2. Global Atopic Dermatitis Market Share (%), by Drug Class, 2021

Global Atopic Dermatitis Market Segmentation:

The global atopic dermatitis market report is segmented into Drug Class, Type of Administration, Prescription Type, and Geography.

Based on Drug Class, the market is segmented into Corticosteroids, Emollients/Moisturizers, IL-4 & PDE4 Inhibitors, Calcineurin Inhibitors Antibiotics, and Other Drug Classes. Out of which, Corticosteroids Segment is expected to dominate the atopic dermatitis market during the forecast period and this is attributed to the increase in usage of corticosteroids. Topical corticosteroids have been the mainstay of treatment for atopic dermatitis.

Emollients/Moisturizers Segment is also expected to witness significant growth in the near future and this is owing to the increase in awareness among people about atopic dermatitis.

Based on Type of Administration, the market is segmented into Topical, Oral, and Injectable. Out of which, Topical Segment is expected to dominate the market over the forecast period and this is attributed to the increase in adoption of topical AD treatments. Topical application remains the primary method for the atopic dermatitis management.

Oral Segment is also expected to witness significant growth in the near future and this is owing to the rise in cases of atopic dermatitis. For severe cases, doctors may prescribe oral corticosteroids, such as prednisone, for the atopic dermatitis management.

Based on Prescription Type, the atopic dermatitis market is segmented into Over-the-counter (OTC) and Prescription. Of which, Over-the-counter (OTC) Segment is expected to dominate the market over the forecast period and this is attributed to the increase in usage of over-the-counter (OTC) drugs to treat atopic dermatitis. Over-the-counter medications that can help prevent flares and assist with sleep are widely available worldwide.

Global Atopic Dermatitis Market: Key Developments

In August 2022, Chugai Pharmaceutical Co., Ltd. announced that Maruho Co., Ltd. announced the launch of anti-IL-31 receptor A humanized monoclonal antibody Mitchga Subcutaneous Injection for the treatment of itching associated with atopic dermatitis. Mitchga is approved by the Ministry of Health, Labour and Welfare (MHLW) on March 28, 2022.

In June 2022, Otsuka Pharmaceutical Co. (Otsuka) announced the launch of Moizerto Ointment (difamilast), a new treatment for atopic dermatitis in Japan.

In February 2022, the U.S. Food and Drug Administration (USFDA) approved the use of Opzelura (ruxolitinib) cream for the topical treatment of mild to moderate atopic dermatitis. They noted that it's for the short-term, non-continuous treatment of chronic atopic dermatitis.

In May 2020, the U.S. FDA approved Dupixent (dupilumab) for children aged six to 11 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Global Atopic Dermatitis Market: Key Companies Insights

The global atopic dermatitis market is highly competitive. This is attributed to the rise in burden or prevalence of atopic dermatitis across the globe, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global atopic dermatitis market are Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.

*Definition: Atopic dermatitis (AD), or eczema, is a chronic condition that causes dry, itchy, and inflamed skin. Atopic dermatitis is long lasting (chronic) and tends to flare sometimes. It’s common in young children but can occur at any age.

Atopic dermatitis (AD), or eczema, is a chronic condition that causes dry, itchy, and inflamed skin. It is the most common chronic skin disease and is genetically transmitted. It can be irritating but it is not contagious. Atopic dermatitis is chronic condition and tends to flare sometimes. It’s common in young children but can occur at any age. There is no cure for atopic dermatitis, and many people have troubling controlling it.

Market Dynamics:

Increasing prevalence of atopic dermatitis across the world, rise in awareness among people about atopic dermatitis, growing government expenditure regarding atopic dermatitis, increase in focus on the development of novel therapeutics, and outbreak of COVID-19 (global pandemic) are major factors expected to drive growth of the global atopic dermatitis market.

For instance, in February 2022, Evelo Biosciences reported that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.

Moreover, in October 2022, LEO Pharma A/S, launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD); the most common form of atopic dermatitis.

Key features of the study:

  • This report provides in-depth analysis of the global atopic dermatitis market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global atopic dermatitis market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global atopic dermatitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global atopic dermatitis market.

Detailed Segmentation:

  • Global Atopic Dermatitis Market, By Drug Class:
    • Corticosteroids
    • Emollients/Moisturizers
    • IL-4 & PDE4 Inhibitors
    • Calcineurin Inhibitors Antibiotics
    • Other Drug Classes
  • Global Atopic Dermatitis Market, By Type of Administration:
    • Topical
    • Oral
    • Injectable
  • Global Atopic Dermatitis Market, By Prescription Type:
    • Over-the-counter (OTC)
    • Prescription
  • Global Atopic Dermatitis Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG
    • Nestle
    • LEO Pharma AS
    • Encore Dermatology Inc.
    • GlaxoSmithKline PLC
    • Allergan PLC
    • AbbVie Inc.
    • Regeneron Pharmaceuticals Inc.
    • Bausch Health Companies Inc.

Frequently Asked Questions

The global atopic dermatitis market size is estimated to be valued at US$ 8,549.8 Million in 2022 and is expected to exhibit a CAGR of 9.7% between 2022 and 2028.
Increasing prevalence of atopic dermatitis and increasing awareness among people is fueling the market.
The Corticosteroids segment is the leading drug class segment in the market.
Adverse effects of certain therapeutic drugs and treatment cost variations limit patient access are major factors restraining the market.
Major players operating in the market are Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo